Log in or register to see all Alerts
New HTA Decisions in England
May 2019
Drug name
LENVIMA® (lenvatinib)
Decision date
Therapeutic area
Therapeutic sub area
Liver cancers
Recommended with restrictions
Treatment of untreated, advanced, unresectable hepatocellular carcinoma in adults
Decision Detail
Patient has Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 The company provides it according to the commercial arrangement
The REFLECT trial provided evidence showing overall survival with lenvatinib is non-inferior compared with its most relevant comparator, sorafenib. Evidence also showed that lenvatinib slows disease progression and causes more tumour shrinkage than sorafenib. Notably, clinical experts highlighted that they may prescribe lenvatinib instead of sorafenib based on individual patient characteristics; lenvatinib and sorafenib have varying side-effect profiles and so tolerability of each drug would depend on the patient. The committee concluded that the most plausible ICER for lenvatinib compared with sorafenib is within the range considered an acceptable use of NHS resources. Lenvatinib could therefore be recommended.